Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185276
Status:
COMPLETED
Last Update Posted:
2014-12-30
First Post:
2005-09-10
Brief Title:
Magnevist Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Randomized Multi-center Open Label Study of the Safety Open-label and Efficacy Open-label Blinded Reader of Magnevist Injection-enhanced Magnetic Resonance Arteriography MRA at Two Dose Levels and 2-dimensional-time-of-flight 2D-TOF MRA in Patients Undergoing MRA of the Infrarenal Aorta and Peripheral Arteries With Intra-arterial Digital Subtraction Arteriography ia DSA as Standard of Reference
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to look at the safety what are the side effects and efficacy how well does it work of Magnevist the study drug used for MRI of the infrarenal aorta and peripheral arteries The results will be compared to the results of MRI taken without Magnevist and with the results of your X-ray angiography
Detailed Description:
This study has previously been posted by Berlex Inc Berlex Inc has been renamed to Bayer HealthCare Pharmaceuticals IncBayer HealthCare Pharmaceuticals Incis the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 306781 | None | None | None |